Historically, large urban academic centres have conducted the majority of clinical trials, leading to such issues as ...

The conversation centred on the company’s latest developments and strategic direction in cancer therapies, with a particular ...

Summit Pharma has revealed that a second pivotal trial of its Akeso-partnered PD-1xVEGF bispecific ivonescimab has failed to ...

What trends did delegates notice, in terms of new modalities, technologies, and approaches? Precision, personalisation, and ...

Op den Kelder grew up in the Netherlands and received his Bachelor’s degree in International Management from Fontys ...

The deal with Evopoint boosts Astellas' claudin pipeline as other CLDN18.2 candidates come through the industry pipeline from ...

Stealth refrained from criticising the FDA's decision on its application, which comes after the agency missed its own ...

Philippe Masset has been appointed to the Board of Directors at Vect-Horus, a French biotech developing vectors for targeting ...

Roche has revealed new results from a phase 2 trial of its oral BTK inhibitor fenebrutinib in relapsing multiple sclerosis (MS) that suggest it can prevent progression of the disease for nearly two ...

Angelini is paying $50 million upfront for ex-North American rights to radiprodil, with another $520 million in the offing in ...

A year ago, MSD and Daiichi Sankyo's HER3-targeting antibody-drug conjugate patritumab deruxtecan (HER3-DXd) was rejected by ...

The award from the Biomedical Advanced Research and Development Authority (BARDA), part of the US Department of Health and ...